Soft Tissue Ablation Made More Predictable

An advanced ablation system offers physicians predictable results regardless of target location or tissue type.

The Emprint Ablation System with Thermosphere Technology is designed to precisely heat and destroy diseased soft tissue, including nonresectable tumors in the liver, lung, and kidney. The system provides clinicians three kinds of spatial energy control (thermal, field, and wavelength) to create spherical ablation zones regardless of target location, tissue type, or changes in tissue properties during a procedure. The system can be used in different procedure settings, including nonsurgical procedures directly through the skin, minimally invasive surgery (MIS), and open surgery.


The system included a 100 W ablation generator with an intuitive user interface and customizable power settings; an internally cooled percutaneous antenna with single body fiberglass construction (available in short, standard, and long lengths); an ablation pump for efficient antenna cooling to minimize thermal conductivity; and a remote temperature probe to verify tissue temperature in real time and trigger automatic ablation shut off when a preset tissue temperature is achieved. The Emprint Ablation System is a product of Covidien (Dublin, Ireland), and has been approved by the US Food and Drug Administration (FDA).

“Covidien is dedicated to improving patient safety and simplifying procedural options, and this innovative technology enables physicians to deliver precise ablation directly to soft tissue, including liver tumors,” said Chuck Brynelsen, president of early technologies at Covidien. “By providing predictable spherical ablation zones, this technology gives physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time.”

Related Links:
Covidien